{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:17:13Z","timestamp":1777519033942,"version":"3.51.4"},"reference-count":2,"publisher":"Massachusetts Medical Society","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2024,10,10]]},"DOI":"10.1056\/nejmc2410841","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T21:08:32Z","timestamp":1728508112000},"page":"1364-1365","source":"Crossref","is-referenced-by-count":4,"title":["Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma"],"prefix":"10.1056","volume":"391","member":"150","reference":[{"key":"e_1_2_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_2_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.4.4"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc2410841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:35:45Z","timestamp":1749681345000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMc2410841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":2,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,10,10]]}},"alternative-id":["10.1056\/NEJMc2410841"],"URL":"https:\/\/doi.org\/10.1056\/nejmc2410841","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}